Significant Revenue Growth
Ardelyx reported a 61% increase in revenue, totaling $74 million compared to the same period last year.
IBSRELA's Strong Performance
IBSRELA achieved a 57% increase in net sales revenue, totaling $44.4 million, supported by strong prescription demand and effective commercial execution.
XPHOZAH's Growth
XPHOZAH revenue grew by 30% compared to last year, with successful patient access across Medicare and non-Medicare segments.
Financial Milestone
Ardelyx earned a $5 million milestone from their partner in China following the approval of Tenapanor for hyperphosphatemia.
Strong Cash Position
As of March 31, 2025, Ardelyx had $214 million in cash, cash equivalents, and short-term investments.